CEACAM1 distribution and it’s effects on angiogenesis and lymphangiogenesis in oral carcinoma

• Published in: Oral oncology Vol. 45; no. 10; pp. 883 - 886
• Main Authors: Zhou, Cheng-Jun, Qu, Xun, Yang, Yong-Mei, Wang, Fu-Fang, Dong, Zuo-Qing, Wang, Cheng-Qin, Zhang, Xiao-Ying, Liu, Gui-Xiang, Wei, Feng-Cai, Sun, Shan-Zhen
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 01.10.2009; Elsevier
• Subjects: Angiogenesis; Antigens, CD - metabolism; Antigens, CD - physiology; Biological and medical sciences; Carcinoma, Squamous Cell - blood supply; Carcinoma, Squamous Cell - metabolism; CEACAM1; Cell Adhesion Molecules - metabolism; Cell Adhesion Molecules - physiology; Endothelial Cells - metabolism; Female; Hematology, Oncology and Palliative Medicine; Humans; Lymphangiogenesis; Lymphangiogenesis - physiology; Male; Medical sciences; Middle Aged; Mouth Neoplasms - blood supply; Mouth Neoplasms - metabolism; Neoplasm Proteins - metabolism; Neoplasm Proteins - physiology; Neovascularization, Pathologic - etiology; Neovascularization, Pathologic - pathology; Oral carcinoma; Otolaryngology; Otorhinolaryngology. Stomatology; Platelet Endothelial Cell Adhesion Molecule-1 - metabolism; Tumors; Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology; Vesicular Transport Proteins - metabolism; Oral carcinoma; Angiogenesis; CEACAM1; Lymphangiogenesis; Cancerology; Stomatology; Oral cavity carcinoma; Distribution; Oral cavity disease; ENT; Malignant tumor; Cancer
• ISSN: 1368-8375; 1879-0593; 1879-0593
• DOI: 10.1016/j.oraloncology.2009.03.002

To investigate the expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and its effects on angiogenesis and lymphangiogenesis in oral carcinoma. Immunohistochemistry was used to study the expression of CEACAM1, LYVE1 and CD31, double-labelling immunofluorescence was used to detect the co-expression of CEACAM1 and LYVE1, and double-labelling immunohistochemistry was performed to observe the co-expression of LYVE1 and CD31 in vessels. Membranous CEACAM1 was expressed in well-differentiated squamous cell carcinoma and cytoplastic CEACAM1 in poorly and moderately differentiated carcinoma ( P < 0.05). More CEACAM1-positive vessels were observed in CEACAM1-positive tumors with cytoplasmic expression than with membranous expression ( P < 0.001). Co-expression of CEACAM1 and LYVE1, LYVE1 and CD31 in vessels was more common in CEACAM1-positive tumors with cytoplasmic expression than with membranous expression ( P < 0.001). CEACAM1 has different distribution in oral carcinoma. Membranous CEACAM1 inhibits angiogenesis and lymphangiogenesis, but cytoplasmic CEACAM1 promotes angiogenesis, and even promotes lymphangiogenesis by mediating the transformation of vascular endothelial cells (VECs) into lymphatic endothelial cells (LECs).